Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Reviews in Cardiovascular Medicine ; 24(1), 2023.
Article in English | Scopus | ID: covidwho-2272011

ABSTRACT

Background: The need for computed tomography pulmonary angiography (CTPA) to rule out pulmonary embolism (PE) is based on clinical scores in association with D-dimer measurements. PE is a recognized complication in patients with SARS-CoV-2 infection due to a pro-thrombotic state which may reduce the usefulness of preexisting pre-test probability scores. Aim: The purpose was to analyze new clinical and laboratory parameters while comparing existing and newly proposed scoring system for PE detection in hospitalized COVID-19 patients (HCP). Methods: We conducted a retrospective study of 270 consecutive HCPs who underwent CTPA due to suspected PE. The Modified Wells, Revised Geneva, Simplified Geneva, YEARS, 4-Level Pulmonary Embolism Clinical Probability Score (4PEPS), and PE rule-out criteria (PERC) scores were calculated and the area under the receiver operating characteristic curve (AuROC) was measured. Results: Overall incidence of PE among our study group of HCPs was 28.1%. The group of patients with PE had a significantly longer COVID-19 duration upon admission, at 10 vs 8 days, p = 0.006, higher D-dimer levels of 10.2 vs 5.3 µg/L, p < 0.001, and a larger proportion of underlying chronic kidney disease, at 16% vs 7%, p = 0.041. From already established scores, only 4PEPS and the modified Wells score reached statistical significance in detecting the difference between the HCP groups with or without PE. We proposed a new chronic kidney disease, D-dimers, 10 days of illness before admission (CDD-10) score consisting of the three aforementioned variables: C as chronic kidney disease (0.5 points if present), D as D-dimers (negative 1.5 points if normal, 2 points if over 10.0 µg/L), and D-10 as day-10 of illness carrying 2 points if lasting more than 10 days before admission or 1 point if longer than 8 days. The CDD-10 score ranged from –1.5 to 4.5 and had an AuROC of 0.672, p < 0.001 at cutoff value at 0.5 while 4PEPS score had an AuROC of 0.638 and Modified Wells score 0.611. The clinical probability of PE was low (0%) when the CDD-10 value was negative, moderate (24%) for CDD-10 ranging 0–2.5 and high (43%) when over 2.5. Conclusions: Better risk stratification is needed for HCPs who require CTPA for suspected PE. Our newly proposed CDD-10 score demonstrates the best accuracy in predicting PE in patients hospitalized for SARS-CoV-2 infection. © 2023 The Author(s). Published by IMR Press.

2.
Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine ; 32(2):265-279, 2021.
Article in English | Scopus | ID: covidwho-1870692

ABSTRACT

Background Despite best efforts, false positive and false negative test results for SARS-CoV-2 are unavoidable. Likelihood ratios convert a clinical opinion of pre-test probability to post-test probability, independently of prevalence of disease in the test population. Methods The authors examined results of PPA (Positive Percent Agreement, sensitivity) and NPA (Negative Percent Agreement, specificity) from 73 laboratory experiments for molecular tests for SARS-CoV-2 as reported to the FIND database, and for two manufacturers’ claims in FDA EUA submissions. PPA and NPA were converted to likelihood ratios to calculate post-test probability of disease based on clinical opinion of pre-test probability. Confidence intervals were based on the number of samples tested. An online calculator was created to help clinicians identify false-positive, or false-negative SARS-CoV-2 test results for COVID-19 disease. Results Laboratory results from the same test methods did not mirror each other or the manufacturer. Laboratory studies showed PPA from 17% to 100% and NPA from 70.4% to 100%. The number of known samples varied 8 to 675 known patient samples, which greatly impacted confidence intervals. Conclusion Post-test probability of the presence of disease (true-positive or false-negative tests) varies with clinical pre-test probability, likelihood ratios and confidence intervals. The Clinician’s Probability Calculator creates reports to help clinicians estimate post-test probability of COVID-19 based on the testing laboratory’s verified PPA and NPA. © 2021 International Federation of Clinical Chemistry and Laboratory Medicine. All rights reserved.

SELECTION OF CITATIONS
SEARCH DETAIL